<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03942601</url>
  </required_header>
  <id_info>
    <org_study_id>CIP0215</org_study_id>
    <nct_id>NCT03942601</nct_id>
  </id_info>
  <brief_title>Temsirolimus Alone or Paired With Dexamethasone Delivered to the Adventitia to eNhance Clinical Efficacy After Femoropopliteal Revascularization</brief_title>
  <acronym>TAP-DANCE</acronym>
  <official_title>Temsirolimus Alone or Paired With Dexamethasone Delivered to the Adventitia to eNhance Clinical Efficacy After Femoropopliteal Revascularization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mercator MedSystems, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mercator MedSystems, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multi-center, pilot feasibility study to document the effects of&#xD;
      adventitial delivery of temsirolimus or temsirolimus with dexamethasone sodium phosphate&#xD;
      injection, USP, after revascularization of femoropopliteal lesions in symptomatic patients&#xD;
      with moderate to severe claudication (Rutherford 2-3) or critical limb ischemia (CLI) with&#xD;
      rest pain (Rutherford 4). Subjects will be followed for up to 60 months post index procedure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To begin to assess the safety and effectiveness of Bullfrog Micro-Infusion Device adventitial&#xD;
      deposition of temsirolimus or temsirolimus with dexamethasone in maintaining luminal patency&#xD;
      and composite safety endpoints in patients with clinical evidence of moderate to severe&#xD;
      claudication or critical limb ischemia with rest pain after revascularization of one or more&#xD;
      angiographically significant lesion(s) in superficial femoral or popliteal arteries.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Anticipated">August 15, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>This is an open-label study without randomization. Cohorts will be enrolled sequentially, with Group 1 followed by Group 2.&#xD;
Study Drug: Temsirolimus Injection (0.4 mg/mL) and 20% contrast in Group 1 or Temsirolimus Injection (0.4 mg/mL), Dexamethasone Sodium Phosphate Injection, USP (3.2 mg/mL) and 20% contrast in Group 2 Route of Administration: Bullfrog Micro-Infusion Device adventitial delivery Dosage Volume:0.5 mL per cm of target vessel length Up to 30 subjects in Group 1 and up to 30 subjects in Group 2. The study shall enroll subjects from up to 20 sites in the United States.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety - Freedom from MALE-POD at 30 days</measure>
    <time_frame>30 days post intervention</time_frame>
    <description>Freedom from MALE-POD at 30 days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effectiveness - Primary patency</measure>
    <time_frame>12 months post intervention</time_frame>
    <description>Primary patency (adjudicate by angio core lab)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effectiveness - Freedom from CD-TLR</measure>
    <time_frame>12 months post intervention</time_frame>
    <description>Freedom from clinically driven target lesion revascularization (CD-TLR)) at 12 months.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>Group 1 - temsirolimus injection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Temsirolimus Injection (0.4 mg/mL) and 20% contrast in Group 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 - temsirolimus and dexamethasone injection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Temsirolimus Injection (0.4 mg/mL), Dexamethasone Sodium Phosphate Injection, USP (3.2 mg/mL) and 20% contrast in Group 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temsirolimus</intervention_name>
    <description>Temsirolimus Injection (0.4 mg/mL) and 20% contrast in Group 1</description>
    <arm_group_label>Group 1 - temsirolimus injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temsirolimus and dexamethasone sodium phosphate</intervention_name>
    <description>Temsirolimus Injection (0.4 mg/mL), Dexamethasone Sodium Phosphate Injection, USP (3.2 mg/mL) and 20% contrast in Group 2</description>
    <arm_group_label>Group 2 - temsirolimus and dexamethasone injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Screening Criteria:&#xD;
&#xD;
          -  Age ≥18 years and ≤85 years at study enrollment&#xD;
&#xD;
          -  Subject has been informed of the nature of the study, agrees to participate and has&#xD;
             signed an IRB-approved consent form&#xD;
&#xD;
          -  Subject is ambulatory&#xD;
&#xD;
          -  Female subjects of childbearing potential have a negative pregnancy test ≤7 days&#xD;
             before the procedure and are willing to use a highly effective method of birth control&#xD;
             (See Section 12.2) for one month preceding and 12 months following study treatment&#xD;
&#xD;
          -  Subject has documented moderate to severe claudication (Rutherford 2-3) or Critical&#xD;
             Limb Ischemia (CLI) with rest pain (Rutherford 4) in the target limb due to arterial&#xD;
             stenosis within the superficial femoral and/or popliteal artery&#xD;
&#xD;
          -  Life expectancy &gt;2 years in the Investigator's opinion Angiographic Criteria (Target&#xD;
             Lesion Definition)&#xD;
&#xD;
          -  Target vessel reference diameter ≥3 mm and ≤8 mm&#xD;
&#xD;
          -  Single or multiple de novo atherosclerotic or restenotic lesion(s) with ≥70% narrowing&#xD;
             in the superficial femoral or popliteal artery meeting the following criteria:&#xD;
&#xD;
               -  The target lesion must be ≤20 cm in total length&#xD;
&#xD;
               -  The target lesion does not have more than 5 cm of contiguous length of&#xD;
                  intervening normal artery&#xD;
&#xD;
               -  The target lesion does not cross into the common femoral artery or tibeoperoneal&#xD;
                  trunk&#xD;
&#xD;
               -  The target lesion is located at least 10 mm away from any previously placed stent&#xD;
                  or graft&#xD;
&#xD;
          -  Successful wire crossing (sub-intimal is allowed) and revascularization by balloon&#xD;
             angioplasty of the target lesion with less than 30% residual stenosis and run-off in&#xD;
             at least one patent vessel into the foot&#xD;
&#xD;
        Exclusion Screening Criteria:&#xD;
&#xD;
          -  Subject is already enrolled in another clinical study of systemic drug therapy or&#xD;
             another device study that has not completed its primary endpoint&#xD;
&#xD;
          -  Subject unwilling or unlikely to comply with visit schedule&#xD;
&#xD;
          -  Subjects who are incapable of providing consent and/or incapable of understanding the&#xD;
             nature, significance and implications of the clinical trial&#xD;
&#xD;
          -  Subject is already receiving, has received in prior 2 months, or is planned in the 6&#xD;
             months after index procedure to receive systemic immunotherapy, chemotherapy, or&#xD;
             systemic steroids (however, steroid pre-treatment for contrast allergy, inhaled&#xD;
             steroids for asthma treatment or topical steroid uses are allowed)&#xD;
&#xD;
          -  Subject is receiving chronic anticoagulation therapy e.g. warfarin (note: chronic&#xD;
             antiplatelet therapy, e.g. aspirin and clopidigrel, and procedural anticoagulation&#xD;
             therapy, e.g. heparin or bivalirudin, are allowed)&#xD;
&#xD;
          -  Subject has a bilirubin level of &gt;1.5xULN&#xD;
&#xD;
          -  Recent (&lt;30 days prior to study procedure) myocardial infarction&#xD;
&#xD;
          -  Cerebrovascular accident &lt;60 days prior to the study procedure or any history of&#xD;
             intracerebral hemorrhage&#xD;
&#xD;
          -  Any surgical or endovascular procedure (not including staged revascularization in the&#xD;
             target limb, e.g. inflow revascularization prior to index procedure or below-knee&#xD;
             revascularization after the index procedure) performed within 14 days prior to the&#xD;
             index procedure or planned within 30 days post index procedure&#xD;
&#xD;
          -  Planned amputation in the target limb&#xD;
&#xD;
          -  Active foot infection or ischemic foot wound&#xD;
&#xD;
          -  Inability to receive temsirolimus, dexamethasone or iodinated contrast medium due to&#xD;
             labeled contra-indications or known sensitivity reactions&#xD;
&#xD;
          -  Estimated glomerular filtration rate (eGFR, calculated from serum creatinine using an&#xD;
             isotope dilution mass spectrometry (IDMS)-traceable equation) less than 30 mL/min&#xD;
             Angiographic/Procedural Criteria&#xD;
&#xD;
          -  Hemodynamically significant inflow lesion (≥50% DS) or occlusion in the ipsilateral&#xD;
             iliac artery in which there is failure to successfully treat and obtain a &lt;30%&#xD;
             residual stenosis post-revascularization, with bailout stenting as needed (in-flow&#xD;
             lesions should be treated prior to treating the target lesion)&#xD;
&#xD;
          -  Prior stent placement in target lesion (i.e., in-stent restenosis)&#xD;
&#xD;
          -  Target lesion restenosis of any kind within 6 months of a prior intervention&#xD;
&#xD;
          -  Use of alternative therapy, e.g. radiation therapy, drug-eluting stents (DES) or&#xD;
             drug-eluting balloon/drug-coated balloons (DEB/DCB) as part of the target lesion&#xD;
             treatment during the index procedure or during the previous 12 months&#xD;
&#xD;
          -  Use of atherectomy devices in the target lesion during the index procedure&#xD;
&#xD;
          -  Aneurysm in the target vessel&#xD;
&#xD;
          -  Acute thrombus in the target limb&#xD;
&#xD;
          -  Heavy eccentric or concentric calcification at target lesion, which in the judgment of&#xD;
             the investigator would prevent penetration of the Micro-Infusion Device needle through&#xD;
             the vessel wall&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kirk Seward, PhD</last_name>
    <phone>(510) 614-4555</phone>
    <email>kseward@mercatormed.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arkansas Heart Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacey Tefetller</last_name>
      <phone>501-614-3641</phone>
      <email>Stacey.Tefteller@arheart.com</email>
    </contact>
    <investigator>
      <last_name>Ian Cawich, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Joseph Hospital of Orange Heart and Vascular Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandy Chung</last_name>
      <email>sandy.chung@stjoe.org</email>
    </contact>
    <investigator>
      <last_name>Mahmood K. Razavi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>San Francisco VA Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohammed Al-Musawi, MD</last_name>
      <email>mohammed.al-musawi@cuanschutz.edu</email>
    </contact>
    <investigator>
      <last_name>Donald Jacobs, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Veterans Administration Hospital</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Corbet</last_name>
      <phone>720-723-6418</phone>
      <email>Michele.corbet@ucdenver.edu</email>
    </contact>
    <investigator>
      <last_name>Ehrin J Armstrong, MD MSc FACC FSCAI FSVM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advocate Christ Medical Center</name>
      <address>
        <city>Oak Lawn</city>
        <state>Illinois</state>
        <zip>60453</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Doherty, RN BSN CCRN</last_name>
      <phone>708-684-4618</phone>
      <email>christopher.doherty@advocatehealth.com</email>
    </contact>
    <investigator>
      <last_name>Jaafer Golzar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center/NYPH</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>North Carolina Heart and Vascular</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Ferguson</last_name>
      <phone>919-784-4279</phone>
      <email>Jennifer.Ferguson@unchealth.unc.edu</email>
    </contact>
    <investigator>
      <last_name>George Adams, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Janelle Bennett</last_name>
      <email>janelle.bennett@uhhospitals.org</email>
    </contact>
    <investigator>
      <last_name>Medhi Shishehbor, DO, PHD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Einstein Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kinnari Murthy, MPH</last_name>
      <phone>215-456-6736</phone>
      <email>MurthyK@einstein.edu</email>
    </contact>
    <investigator>
      <last_name>Jon George, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohammad Shahbazi</last_name>
      <email>Mohammad.Shahbazi@bcm.edu</email>
    </contact>
    <investigator>
      <last_name>Miguel Montero-Baker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>May 6, 2019</study_first_submitted>
  <study_first_submitted_qc>May 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2019</study_first_posted>
  <last_update_submitted>August 31, 2020</last_update_submitted>
  <last_update_submitted_qc>August 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

